Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2003

View Archived Issues

Pfizer presents new CCR1 antagonists for arthritis and other disorders

Novel factor Xa inhibitors developed at BMS

Vertex describes new protein kinase inhibitors

Cytovia scientists design caspase activators and apoptosis inducers

Arizona State U. researchers design new combretastatin A3 prodrugs

Pyrimidine-based tyrosine kinase inhibitors covered by Merck patent

Dual-target antibacterial compounds discovered at Microbiotix

Novel antibacterial isoxazolones prepared and tested by Pharmacia scientists

AnorMED files orphan drug application for AMD-3100

Second phase III study planned for LAX-101

Antex files initial IND for Tracvax

Applied Genetic Technologies' A1AD treatment granted orphan drug status

Positive phase III results obtained for Metformin GR in type 2 diabetes

NP-1 demonstrates efficacy in phase II neuropathy trial

Enrollment completed in phase III trial of MBI-226

Northfield submits response to FDA regarding PolyHeme phase III trial

Goal attainment in donepezil-treated AD patients and correlation with standard measures of efficacy

New phase I trial for VNP-40101M in solid tumors

Improvement of hyperandrogenic alopecia in women after 1-year treatment with flutamide

Grant supports study of HE-2200 for treatment of traumatic shock

AOD-9604 progresses in clinic

SBIR grant supports MitoKor efforts in glaucoma

2C3 antibody inhibits tumor growth by 75%

Preclinical profile of SU-11248 and PK/PD data published

FDA aims to improve and streamline the drug development and review process

Safety of DEAE-rebeccamycin in patients with advanced hepatobiliary cancer

Cialis now available for prescription in several markets

Abbott Japan begins operations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...